P-974 Treatment of non-small cell lung cancer (NSCLC) patients withthe trifunctional bispecific antibody catumaxomab (removab®) (anti-EpCAM × anti-CD3: Results of a phase I study
Sebastian, M., Schmittel, A., Friccius-Quecke, H., Kanniess, F., Wiewrodt, R., Lindhoter, H., Jaeger, M., Passlick, B.
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2005)
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2005)
Get full text
Journal Article